Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation

This publication has 32 references indexed in Scilit:

• Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts
  Journal of Molecular and Cellular Cardiology, 1995
• Repeated measurements and multiple comparisons in cardiovascular research
  Cardiovascular Research, 1994
• Infarct size limitation by preconditioning: its phenomenological features and the key role of adenosine
  Cardiovascular Research, 1993
• Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning
  Cardiovascular Research, 1992
• Role of Kallikrein-Kinin System in the Hypotensive Mechanisms of Converting Enzyme Inhibitors in Essential Hypertension
  Journal of Cardiovascular Pharmacology, 1989
• The mechanism of the hypotensive effect of captopril (converting enzyme inhibitor) with special reference to the kallikrein-kinin and renin-angiotensin systems.
  Japanese Journal of Medicine, 1986
• Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction
  American Heart Journal, 1985
• Effects of Captopril on Limiting Infarct Size in Conscious Dogs
  Journal of Cardiovascular Pharmacology, 1984
• Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size.
  Circulation, 1982
• Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor.
  Circulation, 1982